Recent

% | $
Quotes you view appear here for quick access.

Achillion Pharmaceuticals, Inc. Message Board

ronaldhuffman 4 posts  |  Last Activity: Jul 11, 2016 11:43 PM Member since: Jun 6, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ronaldhuffman by ronaldhuffman Jul 11, 2016 11:43 PM Flag

    Will GILD go private?

  • ronaldhuffman by ronaldhuffman Jun 21, 2016 5:18 PM Flag

    boy did they get a lot of downgrades, just goes to show you these investments brokers are all corrupt. They downgrade and then buy all they can. these guys rig the market and they all need to be jailed

  • ronaldhuffman by ronaldhuffman Jun 16, 2016 3:53 PM Flag

    MRK has a new cancer drug that works, GILD has the money to buy them. Buy MRK.

  • ronaldhuffman by ronaldhuffman Jun 7, 2016 2:15 PM Flag

    Gilead (OP) – GS-5745 Shows Potential in Gastro-esophageal Cancer, Phase 3 Bet Justified. Despite the recent significant setback with Zydelig, Gilead is pushing forward in oncology with GS-5745, its MMP9 inhibitor. At ASCO, Gilead presented data from a Phase 1 study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric cancer. The data supports use of this inhibitor in treatment-naïve patients, which is the setting currently studied in the ongoing Phase 3 study. The best response rate was 55% in treatment-naïve patients vs. 36% in treatment-experienced patients. However, the lack of a control arm (mFOLFOX alone) makes it difficult to ascertain how much of an added benefit GS-5745 provides

ACHN
8.26-0.10(-1.20%)Aug 31 4:00 PMEDT